NEWFLEND ND H9 4000D CONCENTRATE FOR SUSPENSION FOR INJECTION (CELL-ASSOCIATED LIVE RECOMBINANT TURKEY HERPESVIRUS (RHVT/ND-H9) EXPRESSING THE FUSION PROTEIN OF NEWCASTLE DISEASE VIRUS AND THE HEMAGGLUTININ H9-SUBTYPE OF LOW PATHOGENIC AVIAN INFLUENZA)

Dosage

Children: Refer to specific veterinary guidelines or pharmacological references for dosing information, as it varies widely based on the specific drug and condition being treated.

Adults: Refer to specific veterinary guidelines or pharmacological references for dosing information, as it varies widely based on the specific drug and condition being treated.

Mechanism of action

The mechanism of action for avian-related treatments varies widely depending on the specific substance or medication being used. For example, antiviral medications targeting avian influenza viruses may inhibit viral replication by interfering with the viral life cycle, often through mechanisms such as blocking viral entry into host cells or inhibiting viral neuraminidase activity.

Pharmacodynamics

Pharmacodynamics for avian-targeting drugs can include effects on avian physiology, such as modulation of immune response, reduction of viral load, or treatment of bacterial infections. The efficacy and effects depend on the specific condition being treated and the drug's pharmacological profile.

Pharmacokinetics

Pharmacokinetics will differ based on the specific substance being referenced. Typically, this includes absorption, distribution, metabolism, and excretion profiles that are unique to the drug class. In avian species, factors such as species-specific metabolism and physiological differences play crucial roles in how drugs are processed.

Pregnancy

Not enough data available regarding safety in pregnancy. Use with caution and only if the benefits outweigh the risks.

Breast-feeding

Limited data available. Consult a healthcare professional before use.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Dosage

Children: Refer to specific medications used to treat the particular disease for dosing information.

Adults: Refer to specific medications used to treat the particular disease for dosing information.

Mechanism of action

The mechanism of action varies significantly depending on the specific disease in question. For infectious diseases, pathogens may interact with host cells, leading to inflammation, immune response activation, or tissue damage. Chronic diseases often involve complex interactions between genetic factors, lifestyle choices, and environmental influences. For example, in autoimmune diseases, the immune system mistakenly targets healthy cells, leading to inflammation and tissue destruction.

Pharmacodynamics

Pharmacodynamics of disease involves understanding how the disease state affects physiological functions and the body's response to treatment. In infectious diseases, the presence of pathogens can lead to altered immune responses, while chronic diseases may involve changes in metabolic pathways, hormonal balances, or cellular functions. Medications targeting disease processes aim to restore normal function, alleviate symptoms, or eradicate pathogens.

Pharmacokinetics

Pharmacokinetics is not applicable to the term 'disease' as it refers to the movement of drugs within the body, including absorption, distribution, metabolism, and excretion of specific medications used to treat diseases. Each medication will have its own pharmacokinetic profile depending on its chemical properties and the disease being treated.

Indications

• Enzyme replacement therapy
• Monoclonal antibody therapies
• Hormone replacement therapies
• Vaccines
• Gene therapy products

Dosage

Children: Refer to specific product information or clinical guidelines for dosing recommendations, as dosages vary widely based on the specific protein and condition being treated.

Adults: Refer to specific product information or clinical guidelines for dosing recommendations, as dosages vary widely based on the specific protein and condition being treated.

Mechanism of action

The mechanism of action for expressed proteins varies depending on the specific protein involved. Generally, these proteins exert their effects by binding to specific receptors or enzymes in the body, thereby modulating various biological pathways. For example, monoclonal antibodies may bind to antigens on the surface of cancer cells, marking them for destruction by the immune system.

Pharmacodynamics

Pharmacodynamics of expressed proteins is influenced by their concentration, binding affinity, and the presence of specific receptors. The effects can range from cell signaling modulation to immune system activation, depending on the target protein. For instance, therapeutic proteins like insulin lower blood glucose levels by facilitating cellular glucose uptake.

Pharmacokinetics

The pharmacokinetics of expressed proteins can vary widely based on their size, structure, and mode of administration. Typically, these proteins are administered via injection, with absorption rates influenced by factors such as the injection site and formulation. Metabolism often occurs in the liver or kidneys, and the elimination half-life can vary significantly, from hours to several days, depending on the protein's characteristics and the presence of polyethylene glycol or other modifications to prolong circulation.

Pregnancy

Safety in pregnancy has not been established. Use only if clearly needed and the benefits outweigh the risks.

Breast-feeding

Caution is advised. There is limited information on excretion in breast milk.

Storage

Store in a cool, dry place, protected from light.

Indications

• HIV infection
• AIDS

Dosage

Children: Refer to specific product guidelines for dosing information, as it varies by agent and patient condition.

Adults: Refer to specific product guidelines for dosing information, as it varies by agent and patient condition.

Mechanism of action

Fusion inhibitors work by binding to the viral envelope glycoproteins, preventing the conformational changes required for the fusion of the viral membrane with the host cell membrane. This inhibition disrupts the entry of the virus into the host cell, effectively preventing infection and replication.

Pharmacodynamics

The pharmacodynamics of fusion inhibitors involve their ability to bind to specific viral proteins, which are crucial for the fusion process. This interaction results in a dose-dependent effect on the viral load, reducing the number of viral particles capable of infecting new cells. The efficacy of these agents is influenced by the presence of resistant viral strains.

Pharmacokinetics

The pharmacokinetics of fusion inhibitors vary depending on the specific agent but generally include absorption through subcutaneous injection or intravenous administration. They are metabolized in the liver, with varying half-lives that necessitate careful dosing schedules. Elimination is primarily through renal excretion, which should be considered in patients with renal impairment.

Pregnancy

Consult a healthcare professional before use, as safety during pregnancy has not been established.

Breast-feeding

Consult a healthcare professional before use, as safety during breastfeeding has not been established.

Storage

Store at room temperature, away from direct sunlight and moisture.

Indications

• Influenza prevention
• Influenza vaccination

Dosage

Children: Refer to specific vaccine formulations containing hemagglutinin for dosing information, as it varies by vaccine type and strain.

Adults: Refer to specific vaccine formulations containing hemagglutinin for dosing information, as it varies by vaccine type and strain.

Mechanism of action

Hemagglutinin mediates the attachment of the influenza virus to host cells by binding to sialic acid on the cell surface. This binding is essential for viral entry, as it triggers conformational changes in the hemagglutinin molecule, leading to the fusion of the viral and host cell membranes, allowing the viral genome to enter the host cell.

Pharmacodynamics

The pharmacodynamic effects of hemagglutinin are primarily related to its role in viral pathogenesis. The binding of hemagglutinin to host cells initiates the infection cycle, leading to viral replication and the subsequent inflammatory response. The immune system recognizes hemagglutinin as a foreign antigen, prompting the production of antibodies that can neutralize the virus and prevent infection.

Pharmacokinetics

Hemagglutinin is not administered as a drug but is instead produced as part of the influenza virus. Its pharmacokinetics are thus tied to the viral life cycle. Once the virus infects a host, hemagglutinin is expressed on the surface of newly formed virions. The immune response to hemagglutinin involves the production of neutralizing antibodies, which can persist for varying durations, depending on the individual and the specific influenza strain.

Pregnancy

There is limited information on the use of hemagglutinin during pregnancy. Its safety profile has not been well established.

Breast-feeding

Safety during breastfeeding has not been adequately studied, caution is advised.

Storage

Hemagglutinin should be stored at 2 to 8 degrees Celsius and protected from light.

Indications

• Herpes Simplex Virus infection
• Genital herpes
• Cold sores
• Varicella (chickenpox)
• Herpes Zoster (shingles)
• Prevention of herpes virus reactivation in immunocompromised patients

Dosage

Adults: Refer to the BNF for specific dosing recommendations for adults

Mechanism of action

Herpesvirus antiviral medications, such as acyclovir and valacyclovir, primarily inhibit viral DNA synthesis. They are nucleoside analogs that get incorporated into the growing viral DNA chain, leading to premature termination of DNA synthesis. This action is selective for infected cells, as the drugs are activated by viral thymidine kinase, which is present in infected cells but absent in uninfected cells.

Pharmacodynamics

The pharmacodynamic profile of herpesvirus antivirals shows that they are more effective when administered early in the course of the infection. Acyclovir exhibits a higher affinity for viral DNA polymerase than for the host cell's enzymes, which reduces toxicity to human cells. The efficacy of these medications is related to the degree of viral replication; higher viral loads may require higher doses or more frequent administration.

Pharmacokinetics

Acyclovir is well absorbed after oral administration, with a bioavailability of approximately 15-30%. It is widely distributed in body fluids and tissues, including the central nervous system. It undergoes renal excretion, primarily as unchanged drug, necessitating dosage adjustment in patients with renal impairment. The half-life of acyclovir ranges from 2.5 to 3 hours in healthy adults, but this can be prolonged in cases of renal dysfunction. Valacyclovir, a prodrug of acyclovir, has improved bioavailability of approximately 54% and is converted to acyclovir in the body.

Contra-indications

• Hypersensitivity to acyclovir or any of its components
• Severe renal impairment

Adverse effects

• Nausea
• Diarrhea
• Headache
• Dizziness
• Rash
• Renal toxicity
• Neurotoxicity (in cases of rapid infusion or dehydration)

Interactions

• Probenecid may reduce renal clearance of acyclovir
• Other nephrotoxic agents may increase the risk of renal impairment
• Zidovudine may increase the risk of hematological toxicity

Precautions

• Monitor renal function during treatment, especially in patients with pre-existing renal disease
• Hydration is important to prevent crystallization in the kidneys
• Use caution in patients with neurological conditions

Pregnancy

Acyclovir is classified as a category B drug. Animal studies have not demonstrated a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women.

Breast-feeding

Acyclovir is excreted in breast milk in small amounts. Caution is advised when administering to nursing mothers.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

• Oral tablets
• Topical cream
• Intravenous injection
• Oral suspension

Indications

• Prevention of influenza virus infection
• Reduction of the severity of influenza illness
• Protection for high-risk groups against influenza complications

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations for paediatric patients based on age and health status.

Adults: Refer to the BNF for specific dosing recommendations for adult patients based on the type of vaccine and individual health status.

Mechanism of action

Influenza vaccines stimulate the immune system to produce antibodies against the influenza virus. When the body is exposed to the virus, these antibodies help to prevent infection or mitigate the severity of the disease. The vaccines may contain inactivated virus or live attenuated virus, depending on the formulation.

Pharmacodynamics

Upon administration of the influenza vaccine, the immune system recognizes the viral antigens and generates a specific immune response. This response includes the production of antibodies, primarily immunoglobulin G (IgG), which can neutralize the virus and prevent its replication. The response varies based on individual health status and age.

Pharmacokinetics

The pharmacokinetics of influenza vaccines vary by type. After intramuscular or subcutaneous administration, the vaccine components are absorbed into the systemic circulation, leading to the production of antibodies. Peak antibody levels typically occur within 2 to 4 weeks after vaccination. The half-life of antibodies can vary, but they generally persist for several months, providing immunity against future infections.

Interactions

• normal immunoglobulin + influenza vaccine live: Unknown (decreases efficacy)

Pregnancy

Influenza vaccination is recommended during pregnancy, especially in the second and third trimesters, as it protects both mother and fetus.

Breast-feeding

Influenza vaccination is safe during breastfeeding and provides passive immunity to the infant.

Storage

Influenza vaccines should be stored in a refrigerator at 2 to 8 degrees Celsius. Do not freeze.

Indications

• Measles
• Mumps
• Rubella
• Varicella (chickenpox)
• Yellow fever
• Rotavirus
• Intranasal influenza

Dosage

Children: Refer to the BNF for Children for specific dosing information based on age and vaccine type.

Adults: Refer to specific product guidelines for dosing information, as it can vary by vaccine type and brand.

Mechanism of action

Live vaccines work by introducing a weakened or attenuated form of a pathogen into the body. This stimulates the immune system to recognize and respond to the pathogen, leading to the production of antibodies and memory cells that provide long-term protection against future infections by the same pathogen.

Pharmacodynamics

The pharmacodynamics of live vaccines involve the activation of both humoral and cellular immunity. Following vaccination, the immune system generates a robust response, including the production of specific antibodies and the activation of T cells that can recognize and eliminate infected cells. This dual action helps establish long-term immunity.

Pharmacokinetics

The pharmacokinetics of live vaccines vary depending on the specific vaccine. Generally, the vaccine is administered via injection, allowing the live attenuated organisms to enter the bloodstream. The immune response typically begins within days and can last for years, depending on the vaccine. Live vaccines are usually stored under refrigeration to maintain their viability, and they should be administered within their expiration dates.

Interactions

• livevaccines + abrocitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + baricitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + filgotinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + dexrazoxane: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + iron chelators: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + ozanimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + ponesimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + siponimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + upadacitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + diroximelfumarate: Moderate (increases risk of generalised infection (possibly life-threatening))

Indications

• Prevention of Newcastle disease in poultry
• Potential oncolytic therapy in cancer treatment

Dosage

Children: Refer to specific treatment protocols or clinical guidelines for dosages, as they may vary based on the context of use.

Adults: Refer to specific treatment protocols or clinical guidelines for dosages, as they may vary based on the context of use.

Mechanism of action

Newcastle disease virus exerts its effects primarily through the induction of apoptosis in infected cells and the activation of the host immune system. The virus binds to specific receptors on the surface of host cells, facilitating viral entry and replication. It leads to the release of pro-inflammatory cytokines and enhances the anti-tumor immune response in the context of oncolytic therapies.

Pharmacodynamics

The pharmacodynamics of Newcastle disease virus involves its ability to replicate in tumor cells, leading to cell lysis and release of viral progeny that can further infect and destroy adjacent tumor cells. The host's immune system is subsequently activated, enhancing the overall anti-tumor response.

Pharmacokinetics

The pharmacokinetics of Newcastle disease virus is complex, as it involves viral replication and dissemination within the host. Following administration, the virus replicates at the site of infection, with peak viral loads observed at various time points depending on the route of administration and the host's immune status. The virus is typically cleared by the immune system over time, although its persistence can vary based on the type of host cells infected.

Pregnancy

Safety in pregnancy has not been established. Use with caution and only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Safety during breastfeeding is not well established. Caution is advised.

Storage

Store in a cool, dry place away from direct sunlight and heat. Follow specific storage requirements if available.

Indications

• Bacterial infections
• Viral infections
• Fungal infections
• Parasitic infections
• Infectious diseases
• Sepsis
• Pneumonia
• Tuberculosis
• HIV/AIDS
• Malaria

Dosage

Children: Refer to specific guidelines and clinical recommendations for antimicrobial dosing in children based on age, weight, and type of infection.

Adults: Refer to specific guidelines and clinical recommendations for antimicrobial dosing based on the type of infection and pathogen involved.

Mechanism of action

Pathogens typically exert their effects through various mechanisms including adhesion to host cells, invasion of tissues, evasion of host immune responses, and production of virulence factors such as toxins. Each type of pathogen employs specific strategies to infect and damage host tissues.

Pharmacodynamics

The pharmacodynamics of treatments against pathogens involves understanding how these therapies affect microorganisms. Antibiotics, for example, may inhibit cell wall synthesis, disrupt protein synthesis, or interfere with DNA replication in bacteria. Antivirals may inhibit viral replication by targeting specific enzymes involved in the virus life cycle.

Pharmacokinetics

Pharmacokinetics of antimicrobial agents varies widely depending on the class of drug. Factors such as absorption, distribution, metabolism, and excretion are critical in determining the efficacy of treatments against pathogenic infections. For example, the bioavailability of an antibiotic can influence its effectiveness, while the half-life determines dosing intervals.

Pregnancy

Consult a healthcare professional for guidance on the use of pathogenic substances during pregnancy.

Breast-feeding

Consult a healthcare professional for guidance on the use of pathogenic substances while breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight and moisture.

Indications

• Nutritional supplementation
• Muscle repair and growth
• Immune support
• Enzyme replacement therapy
• Hormonal regulation

Dosage

Children: Refer to specific product guidelines for dosing information, as protein requirements in children vary based on age, growth stage, and health status.

Adults: Refer to specific product guidelines for dosing information, as protein requirements can vary widely based on individual needs, activity levels, and clinical conditions.

Mechanism of action

Proteins exert their effects primarily through their structure and interactions with other molecules. They can function as enzymes, hormones, and antibodies, and their action is often mediated by binding to specific receptors or substrates, leading to a change in cellular activity or function. For example, enzymes catalyze biochemical reactions, while antibodies bind to antigens to facilitate immune responses.

Pharmacodynamics

The pharmacodynamics of proteins can vary significantly depending on the specific protein being considered. Generally, the effects of proteins are dose-dependent and influenced by their concentration, affinity for targets, and duration of action. Proteins can have a wide range of biological activities, including promoting cellular repair, regulating metabolism, and modulating immune responses.

Pharmacokinetics

The pharmacokinetics of proteins includes their absorption, distribution, metabolism, and excretion (ADME). Proteins are typically digested in the gastrointestinal tract into amino acids before being absorbed into the bloodstream. Once in circulation, proteins can be distributed throughout various tissues. They may have a variable half-life based on their structure and function, and they are primarily metabolized by the liver and excreted via the kidneys. The pharmacokinetic profile can be influenced by factors such as the route of administration and the presence of other substances.

Pregnancy

Generally considered safe, but high protein intake should be monitored to avoid potential risks.

Breast-feeding

Adequate protein intake is critical for lactating women to support milk production and quality.

Storage

Store in a cool, dry place, away from direct sunlight.

Indications

• Diabetes mellitus
• Chronic kidney disease-related anemia
• Hemophilia
• Cancer (as targeted therapy)
• Autoimmune diseases (e.g., rheumatoid arthritis)

Dosage

Children: Refer to specific product guidelines for dosing information.

Adults: Refer to specific product guidelines for dosing information.

Mechanism of action

Recombinant drugs function by mimicking the action of naturally occurring proteins in the body. For instance, recombinant insulin binds to insulin receptors on target tissues, facilitating glucose uptake and metabolism. Erythropoietin stimulates erythropoiesis by binding to erythropoietin receptors in the bone marrow, promoting the production of red blood cells.

Pharmacodynamics

The pharmacodynamics of recombinant drugs vary depending on the specific protein or hormone being replaced or supplemented. Generally, they exert their effects at the cellular level by interacting with specific receptors, leading to a cascade of biological responses. The therapeutic effects are usually dose-dependent and can vary based on the patient's biological response and the presence of antibodies against the recombinant product.

Pharmacokinetics

Pharmacokinetics of recombinant drugs include absorption, distribution, metabolism, and excretion (ADME) characteristics that can differ significantly based on the specific drug. Many recombinant proteins have a short half-life and require parenteral administration. They are typically distributed throughout the body via the bloodstream, metabolized by the liver and other tissues, and excreted primarily through the kidneys. The pharmacokinetics may be influenced by the patient's age, weight, and overall health.

Pregnancy

Recombinant proteins should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when administering recombinant proteins during breastfeeding, as the effects on the infant are not well established.

Storage

Store in a refrigerator at 2-8 degrees Celsius. Do not freeze, and protect from light.

Indications

• High-quality protein source
• Nutritional support for muscle maintenance
• Source of B vitamins
• Source of selenium
• Source of zinc

Dosage

Children: Protein needs for children vary by age. It is recommended to consult specific dietary guidelines for children, which suggest that the intake of protein should be proportionate to their age, weight, and level of physical activity.

Adults: The recommended dietary allowance for protein varies, but generally, adults require approximately 46-56 grams of protein per day, which can be met through the consumption of turkey as part of a balanced diet.

Mechanism of action

Turkey meat contains proteins that are broken down into amino acids during digestion, which the body utilizes for various physiological functions, including muscle repair, hormone production, and immune function. The presence of tryptophan, an amino acid found in turkey, is known to affect serotonin levels in the brain, which may influence mood and sleep patterns.

Pharmacodynamics

Turkey is rich in amino acids, vitamins, and minerals, which can support overall health. The bioavailability of nutrients such as zinc and B vitamins from turkey contributes to various metabolic processes and functions, including energy production, immune response, and nervous system health. The consumption of turkey is associated with satiety and may impact dietary patterns due to its protein content.

Pharmacokinetics

Nutrient absorption from turkey occurs primarily in the gastrointestinal tract, where proteins are digested into amino acids, and vitamins and minerals are absorbed into the bloodstream. The rate of absorption may vary based on the method of cooking and individual digestive health. Protein metabolism involves hepatic processing, where amino acids are utilized or stored as needed by the body.

Pregnancy

Generally considered safe to consume during pregnancy, but should be cooked thoroughly to avoid foodborne illnesses.

Breast-feeding

Typically safe for breastfeeding mothers, but should be prepared properly to ensure safety for both mother and infant.

Storage

Store in a cool, dry place. Fresh turkey should be refrigerated and consumed within a few days or frozen for longer storage.

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.